Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Apex AI is a pioneering artificial intelligence startup dedicated to early cancer detection and predictive diagnostics. Specializing in stomach and colorectal cancer, our AI-powered platform integrates cutting-edge machine learning models to revolutionize medical diagnostics and patient management. Currently, we are in the commercialization phase, collaborating with leading university hospitals and research institutions to bring AI-driven innovation to clinical practice.
Apex AI is transforming gastrointestinal disease detection through AI-powered predictive analytics and real-time imaging technology.
Stomach Cancer (Gastric Cancer)
AI-driven early detection and risk assessment system
Endoscopic AI analysis for precise identification of early-stage cancer
Colorectal Cancer
Apex AI is at the forefront of medical AI innovation, bridging the gap between research and clinical applications. Our mission is to enhance early disease detection, improve patient outcomes, and streamline medical diagnostics through AI-powered solutions.
AI-powered predictive system for colorectal cancer risk assessment
AI-assisted endoscopic imaging for early colorectal cancer detection
Chronic gastric inflammation leads to a 6-fold increase in atrophic gastritis, progressing to 10-20 times higher cancer risk.
Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, significantly raises the risk of colorectal cancer (up to 7 times higher in severe cases).
80-85% of colorectal cancer cases originate from precancerous polyps, making early detection critical.
United States
Colorectal cancer (15.7%) is the second leading cause of cancer-related deaths in the U.S.
Stomach cancer (4%) is a growing concern, though less common than colorectal cancer.
Digestive cancers make up 19.7% of all cancer cases in the U.S., ranking third among cancer categories. (Source: 2022 American Cancer Society)
Global Trends
Colorectal cancer (9.6%) is among the top 3 most common cancers worldwide.
Stomach cancer (4.9%) is prevalent in high-risk regions like East Asia, Europe, and Latin America.
Digestive cancers account for 14.5% of all cancer cases globally, making them the #1 category of cancer incidence worldwide. (Source: 2024 WHO Report)
With the growing burden of digestive cancers, the market for AI-powered endoscopy and cancer detection solutions is rapidly expanding.
Total GI diagnostic & treatment market: $187 billion
Breakdown by specific cancers:
Stomach cancer: $135 billion
Colorectal cancer: $27 billion
Esophageal and other GI cancers: $26 billion
Global endoscopic screening market (U.S., China, Japan, Europe, Korea): $108 billion
U.S. endoscopic screening market: $63 billion
U.S. AI-assisted endoscopic image interpretation market: $6.3 billion (Assuming a 10% AI adoption rate in the U.S. endoscopy market)
Korean AI-assisted endoscopic image interpretation market: $72 million (Assuming a 10% AI adoption rate in Korea)
Global AI-driven GI diagnostics market: Projected multi-billion-dollar opportunity
Apex AI aims to redefine early cancer detection by leveraging AI to analyze endoscopic images, predict cancer risks, and track disease progression in real time. Our mission is to increase survival rates and optimize clinical workflows by providing AI-assisted precision diagnostics for gastroenterologists worldwide.
With the rapid growth of AI adoption in healthcare, Apex AI is positioned to be a leader in the future of AI-driven cancer diagnostics.
Apex AI has been at the forefront of AI-powered gastrointestinal cancer diagnostics, continuously innovating and expanding through strategic partnerships, R&D breakthroughs, and global commercialization efforts.
Selected for the “TIPS Global Marketing Support Program” (Korea Ministry of SMEs & Startups).
Chosen for the “Smart Healthcare Technology Program”, further strengthening AI-driven healthcare innovations.
Signed strategic business partnership agreement with iKooB for joint commercialization efforts.
Successfully completed the TIPS 2nd Year Program & Startup Commercialization Support Project.
Developed an AI-powered early detection & tracking platform for gastrointestinal cancer risk management.
Conducted multi-hospital clinical studies with Seoul National University Hospital, Yonsei University Severance Hospital, and five other leading medical centers.
Completed the CDW (Clinical Data Warehouse) AI System for Predicting Intradialytic Hypotension (IDH).
Developed and launched an AI-based early detection & tracking system for gastrointestinal cancer risk assessment.
Selected for the TIPS Core Program, validating its potential for AI-driven clinical applications.
Completed AI development for Acute Kidney Injury (AKI) prediction.
Developed new AI-driven diagnostic models for early-stage cancer detection.
Completed a multi-tiered AI platform for Helicobacter pylori-associated stomach cancer risk assessment.
Secured Seed investment from healthcare-focused venture capital.
Selected for Korean government-backed startup acceleration programs, including:
Technology commercialization initiative for innovative SMEs.
Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.
KFDA regulatory approval, and commercialization of AI-powered software for stomach and colorectal cancer diagnostics starting from September 2025.
Certified as a Venture Company.
Incheon National University’s AI healthcare R&D project.
Recognized as the #1 innovation at the 2019 NEMIC (New England Medical Innovation Center) MedTech Bootcamp
High Error Rate in Endoscopic Interpretation
33.6% misdiagnosis rate in gastrointestinal endoscopic evaluations.
Many early-stage abnormalities go undetected due to the complexity of lesions and human error.
Long Asymptomatic Periods
Gastrointestinal cancers remain asymptomatic for up to 10 years, delaying diagnosis.
By the time symptoms appear, cancer is often in an advanced stage with poor survival rates.
Low Survival Rates for Late-Stage Diagnosis
If early detection fails, stomach and colorectal cancer survival rates drop to 20-40%.
Late detection leads to increased treatment costs, reduced quality of life, and higher mortality.
Artificial intelligence can revolutionize early cancer detection by enhancing endoscopic interpretation, reducing diagnostic errors, and enabling proactive cancer monitoring.
AI-Driven Endoscopic Analysis with 90%+ Accuracy
Machine learning models improve endoscopic imaging interpretation, significantly reducing false negatives and misdiagnoses.
Real-time AI assistance helps doctors detect subtle, early-stage abnormalities more effectively.
Continuous Monitoring and Risk Prediction
AI enables longitudinal tracking of precancerous lesions, identifying high-risk patients before cancer develops.
This proactive approach reduces the 10-year diagnostic delay, allowing earlier interventions.
Drastically Improved Survival Rates with Early Diagnosis
Stomach cancer: 96.9% survival rate with early detection.
Colorectal cancer: 93.8% survival rate with early detection.
AI-powered screening helps ensure timely and life-saving interventions.
By integrating AI into gastrointestinal cancer screening, Apex AI aims to bridge the gap between medical imaging limitations and real-world clinical needs. Our AI-driven endoscopic analysis platform has the potential to become a standard tool in global cancer prevention, improving survival rates, reducing costs, and optimizing patient outcomes.
Direct sales targeting major health screening centers and collaborative marketing with the iKooB platform network covering 1,000 hospitals.
Collaboration with Next Biomedical and iKooB for AI-driven digestive health solutions, targeting university hospitals and affiliated research hospitals.
FDA approval application planned for August 2025, with commercialization scheduled for February 2026.
Strategic collaborations:
Harvard MGH: Onboarding two Harvard-affiliated professors as advisors to facilitate expansion into major U.S. medical institutions.
Oracle Healthcare: Establishing strategic partnerships for AI integration.
Medtronic: Building collaborative frameworks for medical AI solutions.
Leveraging local investment networks to enhance market presence and sustainability.
Licensing AI technology to leading Japanese endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.
Strategic collaboration with CEC, a Fujitsu subsidiary, to commercialize solutions within the Japanese healthcare market, including hospitals and screening centers.
Following successful market establishment in Korea, the U.S., and Japan, Apex AI aims to scale into Europe, China, and other high-demand international markets.
Expansion powered by cloud-based AI diagnostic solutions, establishing Apex AI as a global leader in AI-powered gastrointestinal cancer detection.
Apex AI's business model is structured into multiple phases, ensuring gradual market penetration, regulatory compliance, and long-term scalability.
Apex AI is focused on early strategic partnerships and data integration before obtaining regulatory approvals.
Revenue Model
Implementation
Once regulatory approvals are obtained, Apex AI will shift towards direct clinical integration and cloud-based AI services.
The $APEX token is designed with real, sustained utility at the heart of Apex AI’s mission: improving early detection of gastrointestinal (GI) cancers through AI-driven diagnostics.
Apex AI’s web platform enables anyone to securely upload endoscopic images and receive AI-powered diagnostic insights with 95%+ accuracy, surpassing human specialists (~70%).
Each diagnostic transaction creates real demand, linking healthcare usage directly to the token economy.
Users who's local hospitals don't have access to Apex AI can pay for diagnostic reports on Apex Ai's web platform using credit/debit cards.
A portion of the platform’s profits are allocated to buy back and burn $APEX tokens.
With ~250M endoscopies performed annually worldwide (~20M in the U.S.), the addressable market is massive.
As the platform scales globally, token buybacks will grow in parallel—directly rewarding long-term holders.
$APEX also plays a role in Phase 2 of Internet Capital Markets, bridging healthcare innovation with Web3 finance.
$APEX holders can gain exclusive access to Apex AI funding rounds via SPVs managed by D-Day.
Business Partners
Integration with healthcare platforms (e.g., “Doctorbase” by iKooB)
Embedded as a service-based AI platform
Healthcare platform providers
Software sales to hospitals & clinical institutions
Direct sales of clinical support AI software
Medical device distributors
Licensing & data sales to medical device companies
Licensing AI technology for endoscopy & dialysis imaging systems
Endoscopy device manufacturers, AI medical companies
Revenue Model
Implementation
Business Partners
Software licensing & cloud services
Post-approval integration with hospitals, clinics, and insurance providers
Hospitals, health screening centers, insurers
Apex AI has developed a cutting-edge AI-driven early detection system for stomach and colorectal cancer, leveraging over 1 million endoscopic imaging datasets to assist in the diagnosis of precancerous lesions, early-stage cancer, and advanced cancer.
Divides the gastrointestinal tract into 14 anatomical regions for precise localization of abnormalities.
Detects key gastrointestinal conditions, including:
Precancerous lesions: Atrophic gastritis, intestinal metaplasia.
Inflammatory conditions: Gastric ulcers, erosions, colitis.
Apex AI's system offers real-time image analysis, automated abnormality detection, and longitudinal disease tracking.
Patient Search & Data Integration
Connects with electronic medical records (EMR) for streamlined patient data access.
Allows historical comparisons of previous scans for tracking disease progression.
A retrospective clinical study comparing AI-assisted diagnosis with a panel of experienced doctors demonstrated superior accuracy in all key performance metrics.
AI outperformed human doctors in accuracy, sensitivity, specificity, and precision.
The AI model significantly reduces false negatives, ensuring high-risk lesions are detected early.
AI-powered endoscopic analysis can improve diagnostic reliability and reduce misdiagnosis rates, leading to better patient outcomes.
Early-stage stomach and colorectal cancers are often misdiagnosed or missed entirely due to subtle visual characteristics.
AI enhances diagnostic confidence by improving detection accuracy, reducing human error, and supporting physicians in real-time.
By adopting AI-assisted endoscopy, hospitals and clinics can drastically improve cancer survival rates worldwide.
Apex AI is at the forefront of this transformation, providing a next-generation AI diagnostic platform that will shape the future of gastrointestinal cancer detection.
Apex AI is committed to pioneering AI-driven gastrointestinal cancer diagnostics through continuous research and development. Our intellectual property portfolio includes multiple patents and software copyrights, solidifying our leadership in AI-powered medical imaging and predictive diagnostics.
Early and advanced cancers: Stomach and colorectal cancer.
Seamlessly integrates with hospital imaging and endoscopic systems to enhance real-time clinical decision-making.
AI continuously analyzes real-time endoscopic footage, marking potential abnormalities.
Provides a comparative review of previous images to detect disease progression over time.
Time-Based & Region-Based Disease Tracking
Allows doctors to monitor lesion evolution in specific locations within the gastrointestinal tract.
Enhances precision in monitoring high-risk patients over multiple screenings.
High-Resolution Image Processing & Zoom Analysis
Enables doctors to zoom into detected lesions for a more detailed pathological assessment.
Reduces false positives by refining image interpretation.
0.98
Doctor Panel (4 Physicians Average)
67%
69%
55%
70%
0.67
Cancer Risk Prediction
Accuracy
Sensitivity (Recall)
Specificity
Precision
F1 Score
AI (Stomach Cancer)
95%
94%
99%
95%
0.94
AI (Colorectal Cancer)
99%
98%
99%
98%
Status
Patent Number
Title / Description
1
Apex AI
South Korea
Filed
10-2020-0003735
Graph Model-Based AI System for Log Analysis & Batch Scheduling
2
Apex AI
South Korea
Filed
10-2020-0052393
AI-Based Stomach Endoscopy Image Analysis for Cancer Risk Prediction
3
Apex AI
South Korea
Filed
10-2021-0025707
AI-Based Colonoscopy Image Analysis for Colorectal Cancer Risk Prediction
4
Apex AI
South Korea
Filed
10-2021-0025708
AI-Based Gastrointestinal Endoscopy Analysis for Cancer Risk Prediction
5
Apex AI
South Korea
Filed
10-2021-0025709
AI-Based Small Intestine Endoscopy Analysis for Abnormality Detection
6
Apex AI
South Korea
Filed
10-2021-0025710
AI-Based Temporal Medical Image Data Analysis for Disease Onset Prediction
7
Apex AI
South Korea
Filed
10-2021-0026094
Feedback-Based AI Machine Learning Optimization System
8
Apex AI
South Korea
Filed
10-2023-0113554
AI-Based Predictive Model for Disease Onset Using Temporal Medical Data
9
Apex AI
South Korea
Filed
10-2023-0113555
AI-Based Stepwise Learning System for Efficient Machine Learning
Category
Certified By
Certification Number
Description
Software Copyright
Korea Copyright Commission
C-2020-014150
AI Stomach Cancer Prediction Program (AI-powered risk assessment & predictive modeling for gastric cancer)
No.
Patent Holder
Country
Apex AI stands out as the only global AI-powered diagnostic system capable of analyzing both stomach and colorectal cancer at an advanced Level 3 grading system. Unlike competitors, Apex AI provides detailed disease classification and risk stratification, making it a leader in AI-driven gastrointestinal diagnostics.
Only AI system capable of full gastrointestinal lesion classification
Advanced AI grading system differentiates between inflammation, ulcers, polyps, early-stage, and advanced cancer
Applies to both stomach and colorectal cancer detection, whereas most competitors focus on a single organ
Competing AI models mostly differentiate between normal and abnormal tissue.
Apex AI detects the full cancer development process, from precancerous lesions to advanced cancer.
Covers both stomach and colorectal regions, while most competitors specialize in only one.
Provides longitudinal disease tracking, allowing physicians to monitor lesion evolution over time.
Enhances treatment planning and patient lifestyle recommendations based on risk assessment.
Apex AI achieves 95% accuracy for stomach cancer and 98% accuracy for colorectal cancer.
This surpasses competing AI models, which typically lack large-scale datasets and detailed lesion classification.
Apex AI is developing AI-powered dietary analysis to enhance digestive health monitoring.
Future integration will provide dietary recommendations for cancer prevention and treatment.
Continuous optimization has led to superior performance, with stomach cancer detection reaching 95% accuracy and colorectal cancer detection achieving 98% accuracy.
Trained on over 1 million endoscopic images, making it the most comprehensive AI system for gastrointestinal cancer.
Overcomes biases found in small-scale datasets, ensuring robust AI predictions.
Integrates endoscopic imaging with numerical health data, improving AI-driven clinical decision-making.
Fusion of visual and statistical data enhances diagnostic precision and reliability.
With superior lesion classification, unmatched accuracy, and long-term disease tracking, Apex AI is redefining cancer diagnostics. Our mission is to provide AI-powered, life-saving early detection for patients worldwide.
Weisen
Stomach
Estimates risk based on severity
❌ No anatomical mapping
Level 2
Infinite Healthcare
Colorectal
Differentiates between normal & abnormal tissue
❌ No classification of lesions
Level 1
Kaimi
Stomach & Colorectal
Detects abnormal tissue
❌ Cannot classify severity
Level 2
iScope Innovation
Stomach & Colorectal
Detects abnormal tissue
❌ Lacks lesion classification
Level 2
Kwanglim MediTech
Colorectal
Detects abnormal tissue
❌ Lacks lesion classification
Level 2
Apex AI
Stomach & Colorectal
Comprehensive disease detection & severity grading
✅ 14 anatomical regions, multi-stage classification (Inflammation → Ulcers → Polyps → Early-stage → Advanced cancer)
Level 3 (Advanced AI system)
Idot
Stomach
Detects suspicious areas, marks severity
❌ Limited to six lesion types
Level 2